Cysteamine in the treatment of fibrotic disease
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 18, 2016
Issued Date -
N/A
app pub date -
Oct 26, 2011
filing date -
Oct 26, 2011
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Fibrotic diseases are characterized by the replacement of healthy tissue with scar tissue and extracellular matrix in response to tissue damage. Here we describe the reduction of extracellular matrix (ECM) deposition, interstitial fibroblasts, interstitial volume, expression of Collagen I mRNA and protein, expression of profibrotic cytokines and macrophage infiltration by Cysteamine treatment.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully